



MEETING ABSTRACT

Open Access

# PW01-002 – Colchicine resistant FMF in Turkish children

FK Kara Eroglu\*, Y Bilginer, F Ozaltin, R Topaloglu, S Ozen

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switzerland. 22-26 May 2013

## Introduction

At least 5% of familial Mediterranean fever(FMF) patients do not respond to colchicine. We present our initial treatment results with colchicine resistant patients.

## Case Report

### Methods

FMF resistance was defined as having  $\geq 2$  attacks in a month and persistently high CRP and SAA levels during the attack free period, in spite of adequate colchicine dose. All patients were homozygous or compound heterozygotes for MEFV mutations. All continued colchicine treatment at a mean dose of  $0,04 \pm 0,01$  mg/kg.

### Results

Eleven patients with mean age of  $12,7 \pm 7,7$  years (median 14, ranging 1,5-23 years) were studied. These patients were on colchicine treatment for a mean of  $5,5 \pm 4,2$  years. In one patient initially etanercept was used however, this was switched to anakinra since there was no response to anti TNF treatment. A total of 7 patients were started anakinra, however, 2 had local reactions and 2 was unresponsive; they were switched to canakinumab treatment and they all responded with normal acute phase reactants. At this time a total of 8 patients are now being treated with canakinumab with a mean duration of  $10,8 \pm 6,8$  months and 3 patients with anakinra with a mean duration of 19,6 months. One patient who is on anakinra treatment has HIDS mutation as well. There were no side effects.

## Discussion

Anti IL1 treatment is beneficial in FMF patients who are resistant to colchicine and can be used safely.

## Disclosure of interest

None declared.

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A55

Cite this article as: Eroglu et al.: PW01-002 – Colchicine resistant FMF in Turkish children. *Pediatric Rheumatology* 2013 11(Suppl 1):A55.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



Pediatric Rheumatology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey